EUVIMEDEUVIMED entdecken
Delphi-StudieOpen Access · CC BY 4.0

Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management

S Grottoli, P Maffei, A S Tresoldi, S Granato, L Benedan, P Mariani, A Giustina

Journal of Endocrinological Investigation · 29.05.2024 · 47 (12) · 2999-3017

DOI: 10.1007/s40618-024-02386-3 ↗

Kurz gefasst

Delphi-Studie in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 29.05.2024. Verfasst von S Grottoli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy. silvia.grottoli@unito.it. Hauptthemen laut MEDLINE: Acromegaly, Delphi Technique, Receptors, Somatostatin, Drug Resistance. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Torino.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

First-line medical therapy for acromegaly management includes first-generation somatostatin receptor ligands (fgSRLs), but resistance limits their use. Despite international guidelines, the choice of second-line therapy is debated.

Methods

We aim to discuss resistance to fgSRLs, identify second-line therapy determinants and assess glycemia’s impact to provide valuable insights for acromegaly management in clinical practice. A group of Italian endocrinologists expert in the pituitary field participated in a two-round Delphi panel between July and September 2023. The Delphi questionnaire encompassed a total of 75 statements categorized into three sections: resistance to fgSRLs therapy and predictors of response; determinants for the selection of second-line therapy; the role of glycemia in the therapeutic management. The statements were rated on a 6-point Likert scale.

Results

Fifty-nine (79%) statements reached a consensus. IGF-1 levels resulted central for evaluating resistance to fgSRLs, that should be defined considering also symptomatic clinical response, degree of tumor shrinkage and complications, using clinician- and patient-reported outcome tools available. Factors to be evaluated for the choice of second-line medical therapy are hyperglycemia—that should be managed as in non-acromegalic patients—tumor remnant, resistant headache and compliance. Costs do not represent a main determinant in the choice of second-line medical treatment.

Conclusion

The experts agreed on a holistic management approach to acromegaly. It is therefore necessary to choose currently available highly effective second-line medical treatment (pegvisomant and pasireotide) based on the characteristics of the patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyDelphi TechniqueReceptors, SomatostatinDrug ResistanceHumansItalySomatostatinLigandsDisease ManagementSurveys and QuestionnairesHuman Growth Hormone

Stichwörter der Autor:innen

AcromegalyDelphiPasireotidePegvisomantSomatostatin receptor ligands (SRLs)Type 2 diabetes mellitus

Substanzen

Receptors, SomatostatinSomatostatinLigandsHuman Growth Hormone

Autor:innen und Institutionen

  • Department of Medical Science, Division of Endocrinology, Diabetes and Metabolism, University of Turin, Turin, Italy. silvia.grottoli@unito.it.
  • Department of Medicine (DIMED), 3rd Medical Clinic, Padua University Hospital, Padua, Italy.
  • Medical Department, Pfizer Italia, Rome, Italy.
  • Università Milano-Bicocca, Milan, Italy.
  • Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.

Förderung

  • Università degli Studi di Torino

Zitieren

APA

Grottoli, S., Maffei, P., Tresoldi, A. S., Granato, S., Benedan, L., Mariani, P., & Giustina, A. (2024). Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management. Journal of Endocrinological Investigation, 47(12), 2999-3017. https://doi.org/10.1007/s40618-024-02386-3

Vancouver

Grottoli S, Maffei P, Tresoldi AS, Granato S, Benedan L, Mariani P, et al. Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management. Journal of Endocrinological Investigation. 2024;47(12):2999-3017. doi:10.1007/s40618-024-02386-3

BibTeX
@article{Grottoli2024,
  author = {Grottoli, S and Maffei, P and Tresoldi, A S and Granato, S and Benedan, L and Mariani, P and Giustina, A},
  title = {Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management},
  journal = {Journal of Endocrinological Investigation},
  year = {2024},
  volume = {47},
  number = {12},
  pages = {2999--3017},
  doi = {10.1007/s40618-024-02386-3}
}
Kostenlos starten →